Reclast (Novartis Pharmaceuticals Corp.) for bone loss prevention during breast cancer chemotherapy
Record ID 32010000939
English
Authors' objectives:
It has been estimated that 13% of women in the United States will develop breast cancer during their lifetimes. In many women, growth of breast cancer can be reduced by blocking the formation of estrogen with drugs known as aromatase inhibitors. Although these drugs improve the survival of women who have estrogen-responsive breast cancer, blocking estrogen production can cause substantial decreases in bone density, increasing the risk of osteoporosis and bone fractures. Tamoxifen and goserelin have also been used as antiestrogen agents during breast cancer chemotherapy and they can have similar adverse effects on bone density.
Details
Project Status:
Completed
URL for project:
http://www.hayesinc.com
Year Published:
2009
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Bone Density Conservation Agents
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
2010 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.